INVESTORS & MEDIA

Press Releases

Date Title and Summary View
Toggle Summary Atara Biotherapeutics, Inc. to Present at Upcoming Investor Conferences in September 2015
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that it will present at the investor conferences listed below. Citi's 10th Annual Biotech Conference at 11:00 a.m. EDT, Thursday, September 10, 2015 at the Mandarin Oriental New
View HTML
Toggle Summary Atara Biotherapeutics Announces Completion of Enrollment in PINTA 745 Phase 2 Clinical Trial in End-Stage Renal Disease Patients With Protein Energy Wasting
Preliminary Top-Line Data Expected by the End of the Fourth Quarter of 2015
View HTML
Toggle Summary Atara Biotherapeutics Announces Second Quarter 2015 Results
SOUTH SAN FRANCISCO, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today reported financial results for the second quarter ended June 30, 2015.
View HTML
Toggle Summary Atara Bio Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., July 15, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced the closing of its underwritten public offering of 3,980,768
View HTML
Toggle Summary Atara Bio Announces Pricing of Its $180.0 Million Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced the pricing of its underwritten public offering of 3,461,538
View HTML
Toggle Summary Atara Bio Announces Proposed Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., July 7, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced that it has commenced an underwritten public offering of
View HTML
Toggle Summary Atara Biotherapeutics Exercises Exclusive License to T-Cell Technology From Memorial Sloan Kettering Cancer Center
Activated T-Cell Technology Designed to Harness Immune System to Fight Cancer and Infectious Disease
View HTML
Toggle Summary Atara Biotherapeutics, Inc. to Present at Upcoming Investor Conferences in June 2015
SOUTH SAN FRANCISCO, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that it will webcast its presentations at the below listed investor conferences in June 2015. Isaac Ciechanover, the company's President and Chief Executive Officer, will present
View HTML
Toggle Summary Update: Atara Biotherapeutics' Collaborating Investigators to Present Data at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
Atara Biotherapeutics' Collaborating Investigators to Present Clinical Data on T-Cell Therapy for EBV+ Lymphoma after Hematopoietic and Solid Organ Allografts at the 2015 American Society of Clinical Oncology Annual Meeting
View HTML
Toggle Summary Atara Biotherapeutics' Collaborating Investigators to Present Data at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
Atara Biotherapeutics' Collaborating Investigators to Present Clinical Data on T-Cell Therapy for EBV+ Lymphoma After Hematopoietic and Solid Organ Allografts at the 2015 American Society of Clinical Oncology Annual Meeting
View HTML